Q3FY22 Quarterly Result Announced for Alkem Laboratories Ltd.
Pharmaceuticals company Alkem Laboratories declares Q3FY22 result: Total Revenue from Operations was Rs 26,190 million, year-on-year growth of 13.0% India sales were Rs 18,156 million, year-on-year growth of 19.9% International sales were Rs 7,709 million, year-on-year decline of 0.4% Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was Rs 4,985 million, resulting in EBITDA margin of 19.0% vs. 22.8% in Q3FY21. EBITDA declined by 5.8% YoY R&D; expenses for the quarter was Rs 1,449 million, or 5.5% of total revenue from operations compared to Rs 1,335 million in Q3FY21 at 5.8% of total revenue from operations Profit before tax (PBT) was Rs 4,639 million, a decline of 14.6% compared to Q3FY21 Net Profit (after Minority Interest) was Rs 5,257 million, year-on-year growth of 16.6% Commenting on the results, Sandeep Singh, Managing Director, Alkem said, "Our India branded business delivered yet another quarter of market beating performance led by our acute portfolio which partly benefited from the COVID-19 tailwinds. Even our trade generic business continued its healthy growth momentum despite the high base of last year. However, our US business continues to face significant pricing pressure, which we are trying to mitigate through new product launches. We have generated healthy free cash/lows during year which has further strengthen our balance sheet with net cash position of about Rs 15bn." Result PDF04-02-2022